Olivier Samyn is “astonishingly good in pharma litigation” and frequently represents domestic and international companies in contentious proceedings.
Olivier Samyn is one of the founding partners of the law firm Lmt Avocats, created in 1991. He manages the life sciences team alongside Antoine Lemétais. Olivier focuses on litigation before commercial, criminal and administrative courts, as well as professional associations courts. Thanks to his training at HEC and more than 30 years’ experience of giving advice and assistance to stakeholders in this field, Antoine is specifically in charge of contractual matters and transactions involving the merger or transfer/acquisition of products or companies.
Over the years, the expertise of Olivier’s life sciences team, joined in 2012 by a new asset, Ghislaine Issenhuth, Doctor in Law, has broadened both in terms of skills areas (regulation, delisting, price reduction, promotion and distribution of medicines and medical devices, industry/healthcare professional relations, e-health, liability for defective products; manufacturing, distribution and service agreements, assignment and acquisition transactions, intellectual property) and applicable products (drugs, medical devices, labile blood products, blood-derived medicinal products, veterinary medicinal products, food supplements, biocides, cosmetics and phytopharmaceutical products). Thus, the services of Lmt Avocats is diversified accordingly, with tasks including litigation in the field of advertising of a medicinal product, challenges to marketing authorisation applications, price reduction, lawsuits for the liability of pharmaceutical firms, litigation in unfair competition, review of health product promotion, development of health mobile apps, advice on anti-gift law and transparency practices, and defence of originator and generic companies before criminal courts, among other matters.
Olivier Samyn is committed to offering his clients a complete range of services, at pretrial and trial stages, in both contractual and regulatory fields. He has an ever-renewed appetite for new, uncharted fields, such as telemedicine and e-health applications.